|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HIF-1 is functionally expressed in thyroid carcinomas and is regulated not only by hypoxia but also via growth factor signalling pathways and, in particular, the PI3K pathway.
|
19808899 |
2010 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thyroid cancer is frequently associated to the activation of specific protein (RET, BRAF) and lipid [PI(3)K] kinases.
|
17891251 |
2007 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the data of this study suggested that naringin presented anti-tumor effects in TC cells through inhibiting TC cell proliferation and inducing cell apoptosis via regulating the expression of cell proliferation and apoptosis related genes and PI3K/AKT pathway activation.
|
31727500 |
2019 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We recently showed that autocrine production of interleukin (IL)-4 and IL-10 controls thyroid cancer cell survival, growth, and resistance to chemotherapy through activation of Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) and phosphatidylinositide 3'-OH kinase (PI3K)/Akt pathways.
|
17545635 |
2007 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Demethylating the hypermethylated REC8 gene restored its expression in thyroid cancer cells in which the PI3K pathway was genetically over-activated and induced expression of REC8 protein inhibited the proliferation and colony formation of these cells.
|
26472282 |
2015 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that miR-145 is a master regulator of thyroid cancer growth, mediates its effect through the PI3K/Akt pathway, is secreted by the thyroid cancer cells, and may serve as an adjunct biomarker for thyroid cancer diagnosis.
|
24781864 |
2014 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This genotype-based targeting of the PI3K/Akt pathway using Akt and mTOR inhibitors may offer an effective therapeutic strategy for thyroid cancer and warrants further studies.
|
19706758 |
2009 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These distinct genetic alterations constitutively activate the MAPK, PI3K and β-catenin signaling pathways, which have been implicated in thyroid cancer development and progression.
|
23128507 |
2013 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, the role of PI3K pathway activation in thyroid cancer is discussed, with a focus on recent advances.
|
18502332 |
2008 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our data showed that the c-Met/PI3K/Akt signaling pathway was responsible for the inhibitory effect of ING5 on the thyroid cancer.
|
29272787 |
2018 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Targeting mutations leading to PI3K/mTOR/Akt activation are of interest in thyroid cancer.
|
29301825 |
2018 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates a genetic selectivity of MK2206 in inhibiting thyroid cancer cells by targeting the PI3K/Akt pathway, supporting a clinical trial in thyroid cancer.
|
21289267 |
2011 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanically, our data demonstrated that tumor-promoting role of N-cadherin in thyroid cancer was closely related to the activities of the MAPK/Erk, the phosphatidylinositol-3-kinase (PI3K)/Akt and p16/Rb signaling pathways in addition to affecting the EMT process.
|
28042956 |
2017 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present review focuses on the most recent developments on the role of the PI3K/Akt pathway in the pathogenesis of non-medullary TC and will provide insight into how this pathway can be targeted either alone or in the context of multimodal therapeutic strategies for treatment of advanced TC.
|
26138515 |
2015 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/Akt pathway may thus be a major therapeutic target in thyroid cancers.
|
17317825 |
2007 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As in many other human cancers, overactivation of the phosphotidylinositol 3-kinase (PI3K)/Akt signaling pathway occurs frequently in thyroid cancer, but the mechanism is not completely clear.
|
15928251 |
2005 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As phosphoinositide 3-kinase/protein kinase-B (PI3K/AKT) signaling is a fundamental oncogenic driver in many thyroid cancers, we explored a potential role for miR-146b and its target genes in PI3K/AKT activation.
|
29353884 |
2018 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long Noncoding RNA LINC003121 Inhibits Proliferation and Invasion of Thyroid Cancer Cells by Suppression of the Phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Pathway.
|
29969438 |
2018 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to determine the therapeutic efficacy of simultaneously targeting these pathways in thyroid cancer with a single agent and to evaluate biomarkers of treatment response.<b>Experimental Design:</b> CUDC-907 is a first-in-class compound, functioning as a dual inhibitor of HDACs and the PI3K/AKT pathway.
|
28600475 |
2017 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic alterations in pathways, including the mitogen‑activated protein kinase (MAPK)/extracellular signal‑regulated kinase (Erk) and phosphatidylinositol‑3‑kinase (PI3K)/protein kinase B (Akt) pathways, are the driving force behind the development of differentiated thyroid cancer cases into aggressive and undifferentiated forms of thyroid cancer.
|
30365150 |
2019 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, combined PI3K/mTOR and CDK4/6 inhibition is a highly promising novel approach for the treatment of aggressive, therapy-resistant thyroid cancer.
|
30699064 |
2019 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we identify Janus kinase/signal transducers and activators of transcription (STAT) and phosphatidyl inositol 3-kinase (PI3K)/AKT as the down-stream pathways through which these cytokines confer resistance to cell death in thyroid cancer.
|
19638576 |
2009 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that EDAG-1 regulates the proliferation and apoptosis of thyroid carcinoma via the PI3K/Akt signaling pathway.
|
27261581 |
2016 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings may add to the concept of targeting the PI3K pathway in advanced thyroid cancers.
|
27258970 |
2016 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K inhibitors IC87114 inhibits the migration and invasion of thyroid cancer cell in vitro and in vivo.
|
29236327 |
2018 |